Non-interventional, real-world study of patients with early stage, human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC) receiving Trazimera (VESTA)

First published 19/12/2019

Last updated 19/12/2019

EU PAS number:

EUPAS32829

Study

Planned

Download as PDF

Documents

Study protocol

Initial protocol

Pfizer B3271014 Trazimera Real World Evidence Protocol v1 05Sep2019

English (1014.52 KB - PDF) View document

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Non-interventional, real-world study of patients with early stage, human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC) receiving Trazimera (VESTA)

Secondary tabs

Share this page